Fig 1: Identification of S100a6 in the MAPK signaling pathway as a novel biomarker for inflamed AKI-ECs.A In combination with known renal EC biomarkers (Supplemental Fig. S17A) for cell type identification of separated ECs, a total of 6 subclusters with 3 distinct EC subpopulations were identified. B Compared to the Control model, the AKI model identified more ECs, and the UUO, FA and SO models were closer in subpopulation proportions compared to the IRI and CP models. C The top KEGG pathways enriched to each ECs subpopulation showed that immune and inflammation-related pathways were mainly occurring in Clsuter1, 3, 4, 5, and 6, involving all three endothelial cell subtypes, and the classical TNF and MAPK signaling pathways were activated. D The MAPK signaling pathway in AKI-ECs, with S100a6 being one of the activating genes of this pathway. E The DEGs of ECs1-6 were correlated with the proteome of UUO, and S100a6 was upregulated at both transcriptional and translational levels. F S100a6 was more significantly expressed in ECs compared to PTCs. Kruskal-Wallis test, ***P < 0.001 vs. Ctrl group. G In the IRI multi-time-point snRNA-seq dataset (GSE139107), S100a6 was upregulated at the second day after kidney injury and declined subsequently. H High expression of S100a6 was correlated with high levels of creatinine. I Through ROC diagnostic curve, the diagnostic efficacy of S100a6 in differentiating diseases was tested in the AKI public datasets GSE98622 (AUC:0.824, CI:0.707-0.942) and GSE139061 (AUC:0.590, CI:0.338-0.841). J Immunofluorescence staining validates S100a6 (red) in AKI-ECs, Scale bars = 100 µM. Quantitative analysis of protein immunofluorescence intensity in Supplemental Fig. S7C.
Supplier Page from RayBiotech for Mouse S100A6 ELISA